Conclusions Our study did not identify predictive or prognostic factors for IO outcomes in unresectable PM, emphasizing the complexity and heterogeneity of PM. Further research with larger cohorts is crucial to unveil biomarkers in this setting.

3 months ago

Clinical • Tumor mutational burden • IO biomarker

PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BAP1 (BRCA1 Associated Protein 1) • NF2 (Neurofibromin 2) • FANCA (FA Complementation Group A)

PIK3CA mutation • BAP1 mutation • NF2 mutation • FANCA mutation

FoundationOne® CDx • OmniSeq INSIGHT

6ms

Findings of clinically significant variants (Tier IA) with OmniSeq INSIGHT Â® in a breast cancer cohort of 987 patients (SABCS 2023)

CGIP for breast cancer patients identified one or more clinically significant Tier IA genomic alterations that directs targeted therapy in ~ 37.5% of patients in a cohort of real world patients tested during the standard course of clinical care. This highlights the need for comprehensive genomic testing in breast cancer patients to drive therapeutic decision making.

6 months ago

Clinical • Tumor mutational burden • PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • PALB2 (Partner and localizer of BRCA2)

PD-L1 expression • NTRK1 fusion • NTRK3 fusion

OmniSeq INSIGHT

almost2years

Labcorp expands access to comprehensive genomic testing through new lung cancer program (LabCorp Press Release)

"Labcorp...is announcing a new sponsored testing program aimed at helping advanced non-small cell lung (NSCLC) cancer patients and their physicians make informed treatment and care management decisions through comprehensive genomic insights...The program will use Labcorp’s OmniSeq INSIGHT^SM test, a pan-cancer, tissue-based sequencing test, to provide comprehensive genomic and immune profiling for cases that meet eligibility criteria."

almost 2 years ago

Clinical

OmniSeq INSIGHT

over2years

GenomOncology Pathology Workbench to Support OmniSeq INSIGHT, a Genomic and Immune Proﬁling Test That Identiﬁes Potential Treatment and Clinical Trial Options for Solid Tumors (PRNewswire)

"GenomOncology announced today that GenomOncology (GO) Pathology Workbench has been selected by Labcorp's OmniSeq to support the analysis and reporting of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling test for solid tumors....OmniSeq INSIGHT examines the full coding region of 523 genes by next generation sequencing for mutations, copy number alterations, fusions microsatellite instability (MSI), tumor mutation burden (TMB), and expression of 64 immune genes in the tumor microenvironment. The test also includes PD-L1 by immunohistochemistry."

over 2 years ago

Clinical

OmniSeq INSIGHT

almost3years

OmniSeq receives New York State approval for cancer genomic, immune proﬁling test (OmniSeq Press Release)

"OmniSeq said on Tuesday that it has received approval from the New York State Department of Health's Clinical Laboratory Evaluation Program for its Insight cancer genomic and immune profiling test...With the approval, the test, which detects genomic variants, genomic signatures, and immune gene expression to inform cancer treatment decisions, will be available to patients in New York."

almost 3 years ago

Regulatory

OmniSeq INSIGHT

TEST:OmniSeq INSIGHT

News

TEST:
OmniSeq INSIGHT